Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tianyin Pharmaceutical, a manufacturer and supplier of modernized traditional Chinese medicine based in Chengdu, China, has received approval from the Chinese State Food and Drug Administration to produce Laonian Kechuan tablets in the dosage form of 0.25 gram/tablet.
Subscribe to our email newsletter
Tianyin said that Laonian Kechuan tablet is a traditional Chinese medicine drug that effectively treats asthma in people aged 60 or above. The company plans to launch Laonian Kechuan tablets in the domestic market and begin recording revenue in November 2008.
Tianyin added that the clinical trials showed that the company’s Laonian Kechuan tablets can effectively boost immunity and improve the recovery of elder patients with asthma. The drug is also effective in treating chronic bronchitis and related indications such as physical weakness, the company said.
Jiang, chairman and CEO of Tianyin Pharmaceutical, said: “We expect to begin production of Laonian Kechuan tablets by late September and will leverage our national distribution network, including over 700 salespeople, to ensure a successful commercialization of this new drug beginning in November 2008.
“Currently we maintain the capacity to produce approximately one million tablets of this product monthly. As China’s elderly population is rising so rapidly, we anticipate this new drug will be another significant contributor to growth of our revenue and net income.”